Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment

ONCOEXTRA / RISKGUARDInitiative advances precision cancer medicine by bringing comprehensive genomic profiling and hereditary cancer tests to patients at the Mayo Clinic Comprehensive Cancer Center

ROCHESTER, Minn. & MADISON, Wis.–(BUSINESS WIRE)– Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of an initiative with Mayo Clinic to provide comprehensive genomic profiling and hereditary cancer tests to patients. The initiative expands the collection of data accessible to Mayo Clinic researchers and clinicians to advance cancer research and patient care.

“This collaboration supports our mission to help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment,” said Kevin Conroy, chairman and chief executive officer, Exact Sciences. “By combining the strength of Exact Sciences’ portfolio of tests with Mayo Clinic’s world-renowned medical and scientific expertise, we’ll help put cancer patients on a path to potentially more effective, targeted therapies and better outcomes.”

Specialists at Mayo Clinic Comprehensive Cancer Center care for more than 130,000 unique cancer patients each year at three Mayo Clinic Comprehensive Cancer Center sites across the United States: Rochester, Minnesota and the Upper Midwest: Phoenix and Scottsdale, Arizona; and Jacksonville, Florida. Having access to the results from Exact Sciences’ comprehensive genomic profiling test, OncoExTra® , and hereditary cancer test, Riskguard™ , will help guide therapeutic decisions, advance cancer research, and support the development of new diagnostic tests and therapies for cancer treatment.

Full press release